Skip to main content
. 2016 Nov 11;8(15):24303–24313. doi: 10.18632/oncotarget.13286

Figure 2. Prognostic relevance of ERCC1+CTCs after chemotherapy.

Figure 2

A patient was considered positive for ERCC1+CTCs if at least one of the AdnaTest transcript markers (EpCAM, MUC-1 or CA-125) was detected, in addition to ERCC1-positivity. The Kaplan-Meier analysis shows A. progression-free survival and B. overall survival of patients with detectable ERCC1+CTCs after platinum-based chemotherapy (bottom curves) in comparison to patients with non-detectable ERCC1+CTCs (top curves).